Akifumi Morinaka
Directeur/Bestuurslid bij Rege Nephro Co. Ltd.
Profiel
Akifumi Morinaka is currently working as an Outside Director at Rege Nephro Co. Ltd.
and as a Principal at JAFCO Group Co. Ltd.
(Private Equity) since 2019.
He previously worked as an Outside Director at Chordia Therapeutics, Inc.
Actieve functies van Akifumi Morinaka
| Bedrijven | Functie | Begin |
|---|---|---|
JAFCO Group Co. Ltd. (Private Equity)
 JAFCO Group Co. Ltd. (Private Equity) Investment ManagersFinance JAFCO Group Co. Ltd. (JAFCO Group) is the private equity arm of the parent firm, JAFCO (TSE: 8595), founded in 1973. The firm is headquartered in Tokyo, Japan. | Private Equity Investor | 01-11-2019 |
Rege Nephro Co. Ltd.
 Rege Nephro Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Rege Nephro Co. Ltd. is a company based in Kyoto, Japan that specializes in the research, development, production, and sales of renal disease treatment drugs. The Japanese company has developed a unique and realistic approach to induce high-efficiency differentiation from stem cells, with the aim of saving patients suffering from renal failure. The company's research and development activities focus on developing various solutions for renal disease and improving the quality of life of patients suffering from renal disease. Rege Nephro Co. was founded in 2019 by Kenji Nagafune. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Akifumi Morinaka
| Bedrijven | Functie | Einde |
|---|---|---|
| CHORDIA THERAPEUTICS INC. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
JAFCO Group Co. Ltd. (Private Equity)
JAFCO Group Co. Ltd. (Private Equity) Investment ManagersFinance JAFCO Group Co. Ltd. (JAFCO Group) is the private equity arm of the parent firm, JAFCO (TSE: 8595), founded in 1973. The firm is headquartered in Tokyo, Japan. | Finance |
Chordia Therapeutics, Inc.
 Chordia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chordia Therapeutics, Inc. engages in the research and development of novel therapies for cancers. It handles research and development of low-molecular-weight drugs with unprecedented new mechanisms of action in the oncology area. The company was founded by Hiroshi Miyake and Daisuke Morishita on October 12, 2017 and is headquartered in Fujisawa, Japan. | Health Technology |
Rege Nephro Co. Ltd.
Rege Nephro Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Rege Nephro Co. Ltd. is a company based in Kyoto, Japan that specializes in the research, development, production, and sales of renal disease treatment drugs. The Japanese company has developed a unique and realistic approach to induce high-efficiency differentiation from stem cells, with the aim of saving patients suffering from renal failure. The company's research and development activities focus on developing various solutions for renal disease and improving the quality of life of patients suffering from renal disease. Rege Nephro Co. was founded in 2019 by Kenji Nagafune. | Commercial Services |
